昊海生物科技(06826.HK)料中期淨利2752.7萬元 同比減少85%
格隆匯 8 月 14日丨昊海生物科技(06826.HK)公告,對集團截至2020年6月30日止6個月未經審核綜合管理帳目作出初步審閲,於報告期內,集團實現未經審核歸屬於上市公司股東的淨利潤預期約人民幣2752.7萬元,與2019年同期相比減少約85%;未經審核歸屬於上市公司股東扣除非經常性損益後的淨利潤預期約人民幣782.99萬元,與2019年同期相比減少約96%。
據董事會所知,報告期錄得利潤較去年同期降低主要由於報告期內新型冠狀病毒肺炎("新冠肺炎")疫情在全球範圍持續蔓延所導致的影響。在報告期間,中華人民共和國("中國")各地實施嚴格的新冠肺炎疫情防控措施,醫療機構門診量及手術量鋭減,導致報告期內集團產品銷售收入同比下降。
與此同時,新冠肺炎疫情在中國以外國家和地區的持續蔓延亦導致2020年第二季度公司海外子公司的生產經營活動受到較大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.